Skip to main
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen Inc is poised for significant financial growth, with management projecting product sales exceeding $18 million in Q1 2026, which indicates a remarkable sequential growth of over five-fold. This anticipated sales increase is supported by commercial momentum, the activation of treatment centers, and a forthcoming reimbursement tailwind from a permanent J-code effective April 1, 2026, leading to enhanced adoption by community physicians. The company's promising clinical pipeline and innovative technology platforms further underpin the positive outlook for its financial performance in the biopharmaceutical market.

Bears say

Precigen Inc. reported disappointing financial results for the fourth quarter of 2025, with sales of $3.4 million significantly below the consensus estimate of $8.3 million. The company also posted a net loss of $0.04 per diluted share, which, while better than the estimated loss of $0.08 per share, still reflects a challenging financial position. These figures indicate ongoing difficulties in revenue generation and profitability, contributing to a negative outlook for the company's stock.

Precigen (PGEN) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 3 analysts, Precigen (PGEN) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.